MarketPulse

photodynamic therapy

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biofrontera to Report Q1 2026 Results as PDT Expansion Accelerates

Biofrontera to report Q1 2026 results May 14, advancing Ameluz® commercialization and clinical expansion into skin cancers and acne.
BFRIBFRIWclinical trialsbiopharmaceutical
BenzingaBenzinga··Soligenix, Inc.

Soligenix's HyBryte Outperforms Valchlor in Cutaneous Lymphoma Study

Soligenix's HyBryte demonstrated superior efficacy versus Valchlor in treating cutaneous T-cell lymphoma, with 60% versus 20% success rates at 12 weeks, backed by $2.6M FDA grant.
SNGXFDA approvalclinical trial
BenzingaBenzinga··Soligenix, Inc.

Soligenix's HyBryte Shows Promise Against Cutaneous Lymphoma at 2026 Workshop

Soligenix's HyBryte™ cutaneous lymphoma therapy shows positive results ahead of 2026 presentation, with FDA awarding $2.6M development grant.
SNGXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Ibn

Soligenix Reports Promising 48% Response Rate in HyBryte Phase 3 Study

Soligenix's HyBryte study shows 48% response rate, nearly double the 25% threshold, with interim results expected this quarter.
SNGXPhase 3 clinical trialbiotech